Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zofran (Ondansetron Hydrochloride),ZOFRAN101,2022,USA,MDV,350,62,55,45,27.5,32,85,12,20,35,30,15,60,25,10,5,25,40,35,18,8,4,10,6,28,65,52,FAC,TC,AC,CMF,22,15,18,25,95,70,15,45,40,60,2
Zofran (Ondansetron Hydrochloride),ZOFRAN102,2023,Canada,Claim Database,420,68,60,40,28.1,28,80,10,18,32,35,15,55,30,10,5,22,38,40,20,10,5,12,7,30,60,50,TC,EC,CMF,Taxol,20,17,13,28,92,72,10,50,40,65,3
Zofran (Ondansetron Hydrochloride),ZOFRAN103,2023,UK,MDV,280,70,52,48,26.9,35,75,8,22,38,25,15,65,20,10,5,28,35,37,22,12,6,14,8,25,70,55,EC,FEC,Taxol,AC,25,12,15,30,90,68,20,40,40,70,2.5
Zofran (Ondansetron Hydrochloride),ZOFRAN104,2024,Australia,Claim Database,480,65,58,42,29.0,30,82,15,19,33,32,16,58,28,9,5,24,39,37,19,9,4.5,11,6.5,27,63,51,FEC,AC,AC,Taxol,21,16,17,26,93,71,12,48,40,62,2.7
